Speaking to Arthritis Digest magazine, Professor Anne Barton explains how a diagnosis of inflammatory arthritis is life changing, but is no longer a life sentence.
A major clinical trial supported by Manchester BRC researchers has found that by interrupting the treatment of vulnerable people on long-term immune supressing medicines for two weeks after a COVID-19 booster vaccination, their antibody response to the jab is doubled.
BRC Musculoskeletal researcher Dr James Bluett talks to Arthritis Digest magazine about how new tests will support patients with rheumatoid arthritis to regain control of their health.
Researchers from Manchester BRC’s Musculoskeletal (MSK) Theme have published the first guidelines on the care and treatment of patients with the rare autoimmune condition, myositis.
Continuing regular contributions from our BRC Musculoskeletal (MSK) theme researchers, Dr Alexander Oldroyd speaks to Arthritis Digest magazine about how technology could potentially help predict flares in patients with the autoimmune condition, myositis.
Three researchers from Manchester Biomedical Research Centre (BRC) have been appointed Senior Investigators by the National Institute for Health Research (NIHR).
The NIHR Immune Mediated Inflammatory Disease (IMID) BioResource recently hit a major recruitment milestone of 2000 volunteers, thanks to the collaborative effort of centres across England.
New research led by University of Manchester and NIHR Manchester Biomedical Research Centre (BRC) scientists has profiled the side effects of methotrexate – a common drug used to treat arthritis and other autoimmune diseases.